| Today’s Big NewsJan 19, 2024 |
| By Nick Paul Taylor Ikena Oncology is going all in on its two lead assets. After missing out on $90 million from Bristol Myers Squibb, the biotech outlined plans to lay off 35% of its workforce and shift resources from drug discovery to clinical development of its two top cancer prospects. |
|
|
|
By James Waldron PMV Pharma is laying off 30% of its staff as the precision oncology biotech prioritizes pushing its lead solid tumor candidate toward a phase 2 trial this year. |
By Nick Paul Taylor Novo Holdings is fattening up as patients slim down. Boosted by the Wegovy windfall, the fund manager's CEO Kasim Kutay expects to do “a fair amount” more deals in 2024 and to open a second office in Asia. |
By Max Bayer,Gabrielle Masson BioMarin's new CEO Alexander Hardy is wasting no time overhauling the company, sending Chief Commercial Officer Jeffrey Ajer for the exits. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
By Gabrielle Masson Mirae Asset Capital Life Science has exited stealth mode with $50 million ready to go for certain U.S. biotechs. |
By Max Bayer Kyverna has nabbed FDA fast track designation for its lead asset to treat multiple sclerosis, adding momentum to its IPO roadshow days after declaring plans to go public. |
By Helen Floersh Scientists from the University of Zurich have released a new study that could explain the mechanism behind the condition—a step towards developing new treatments. |
By Zoey Becker The Senate Committee on Health, Education, Labor, and Pensions will vote on issuing subpoenas at the end of the month after the Johnson & Johnson and Merck CEOs refused to testify at an upcoming hearing. |
By Angus Liu With the metastatic liver cancer field getting increasingly crowded for immunotherapies, AstraZeneca is trying to reach new ground with Imfinzi in locoregional disease. But a regulatory hurdle lies ahead. |
By Kevin Dunleavy A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades. |
By Ayla Ellison,Eric Sagonowsky,Kevin Dunleavy At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. |
By Angus Liu Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S. agency has invalidated a Seagen patent. LegoChem has sold a large stake, worth $411 million, to fuel antibody-drug conjugate R&D. And more. |
Fierce podcasts Don’t miss an episode |
| At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. |
|
|---|
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
